Delta-Fly Pharma, Inc.

4598

JP3549370009

Pharmaceuticals

Delayed Japan Exchange Other stock markets 02:00:00 2024-04-26 am EDT			5-day change	1st Jan Change
778 ^JPY	-2.87%		-2.02%	-23.35%

Apr. 08	Delta-Fly Pharma Inc. Receives Notice of Authorization to Conduct the Phase I/II Study of DFP-10917 Combined with Venetoclax	CI
Mar. 11	Delta-Fly Pharma Inc. Announces FDA Submission of the Protocol of the Phase I/II Study of DFP-10917 Combined with Venetoclax in the AML Patients Treated by VTX in the AML	CI

Delta-Fly Pharma Inc.: FDA submission of the protocol of the Phase I/II study of DFP-10917 combined with Venetoclax (VTX) in the AML patients pretreated by VTX involved one regimen

March 11, 2024 at 07:06 am EDT

Following to the previous information on Jan. 30th. in 2024, we are excited to share our latest development status.

FDA submission of the protocol of the Phase I/II study of DFP-10917 combined with Venetoclax (VTX) in the AML patients pretreated by VTX involved one regimen have been done on March 8^th, 2024.

The Phase I/II study of DFP-10917 with VTX in the above AML patients shall be started at Wake Forest and the other hospitals soon after FDA approval.

The interim analysis of the Phase III study of DFP-10917 in patients with recurrent or refractory acute myeloid leukemia (R/R AML) at multicenter in the US is undergoing for the reason there are patients with a long-term survival may effect on OS analysis.

The invention with the combination of DFP-14927 with VTX in AML was granted in Japan, US, and Taiwan.

Please take notice of our own innovative approach for miserable cancer patients and contact with us.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240311048389/en/

Latest news about Delta-Fly Pharma, Inc.

Delta-Fly Pharma Inc. Receives Notice of Authorization to Conduct the Phase I/II Study of DFP-10917 Combined with Venetoclax	Apr. 08	CI
Delta-Fly Pharma Inc. Announces FDA Submission of the Protocol of the Phase I/II Study of DFP-10917 Combined with Venetoclax in the AML Patients Treated by VTX in the AML	Mar. 11	CI
Delta-Fly Pharma Inc. Announces Abstracts Submission for Phase I Clinical Trial of DFP-14927 to 2024 ASCO Annual Meeting	Feb. 07	CI
Delta-Fly Pharma Inc Announces Initiation of Phase III Pivotal Comparative Clinical Trial of DFP-14323	Feb. 02	CI
Delta-Fly Pharma, Inc. Provides Update on Interim Analysis Status of Phase III Study of DFP-10917 in Patients with R/R AML	Jan. 30	CI
Delta-Fly Pharma, Inc. announced that it has received ¥503.7238 million in funding from Nippon Chemiphar Co., Ltd.	Nov. 09	CI
Delta-Fly Pharma, Inc. announced that it has received ¥1.300842 billion in funding from Macquarie Group Limited	22-12-04	CI
Delta-Fly Pharma, Inc. announced that it expects to receive Ã‘1.300842 billion in funding from Macquarie Group Limited	22-11-16	CI
Delta-Fly Pharma, Inc. announced that it has received ¥5.67 million in funding from Mizuho Securities Co., Ltd., Investment Arm	20-12-23	CI
Delta-Fly Pharma, Inc. announced that it expects to receive ¥5.67 million in funding from Mizuho Securities Co., Ltd., Investment Arm	20-12-07	CI
Delta-Fly Pharma Enters into Licensing Agreement with Nippon Chemifa	20-03-23	CI
Delta-Fly Pharma, Inc. Initiates Phase 3 Clinical Study of DFP-10917 and Phase 1 Clinical Study of DFP-14927	19-11-26	CI
Certain Common Shares of Delta-Fly Pharma, Inc. are subject to a Lock-Up Agreement Ending on 9-JAN-2019.	19-01-08	CI
Delta-Fly Pharma, Inc. has completed an IPO in the amount of ¥3.339 billion.	18-10-11	CI
Delta-Fly Pharma, Inc. has filed an IPO.	18-09-05	CI
Delta-Fly Pharma, Inc. announced that it has received funding from Sanyo Chemical Industries Ltd.	18-03-22	CI

Chart Delta-Fly Pharma, Inc.

Duration

Period

More charts

Company Profile

Delta-Fly Pharma, Inc. is a Japan-based company principally engaged in the research, development, manufacture and sale of pharmaceuticals. The Company's development pipeline includes anticancer drug candidate compound DFP-10917 whose target disease is refractory or recurrent acute myelogenous leukemia, anticancer drug candidate compound DFP-14323 whose target disease is lung cancer, anti-cancer drug candidate compound DFP-11207 whose target disease is solid cancer, anticancer drug candidate compound DFP-14927 whose target disease is solid cancer or blood cancer, anticancer drug candidate compound DFP-10825 whose target disease is peritoneal dissemination metastatic cancer.

Sector

Pharmaceuticals

Calendar

2024-05-14 - Q4 2023 Earnings Release

More about the company

	1st Jan change	Capi.
DELTA-FLY PHARMA, INC.	-23.35%	40.67M
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals